Evidence map›Paper›PMID 26651848›Full record

ArticleAmerican journal of respiratory and critical care medicine2016

High-Density Genetic Mapping Identifies New Susceptibility Variants in Sarcoidosis Phenotypes and Shows Genomic-driven Phenotypic Differences.

Natalia V Rivera, Marcus Ronninger, Klementy Shchetynsky, Andre Franke, Markus M Nöthen, Joachim Müller-Quernheim, Stefan Schreiber, Indra Adrianto, Bekir Karakaya, Coline H M van Moorsel and 11 more

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory and critical care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 90 citations in OpenAlex.

  1. Trial
  2. Quality of Life in Sarcoidosis.Diagnostics (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. WASOG 2023 conference highlights.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024
    Article
  9. Article
  10. Article
  11. Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Pulmonary granulomatosis of genetic origin.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  20. Epigenetics and sarcoidosis.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 6 countries.

Natalia V Rivera1 Respiratory Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Marcus Ronninger1 Respiratory Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Klementy Shchetynsky2 Center for Molecular Medicine, and.
Andre Franke4 Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Markus M Nöthen5 Institute of Human Genetics, and.
Joachim Müller-Quernheim7 Department of Pneumology, University of Freiburg, Freiburg, Germany.
Stefan Schreiber4 Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Indra Adrianto10 Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
Bekir Karakaya11 Center of Interstitial Lung Diseases, St. Antonius Hospital, Nieuwegein, the Netherlands.
Coline H M van Moorsel11 Center of Interstitial Lung Diseases, St. Antonius Hospital, Nieuwegein, the Netherlands.
Zdenka Navratilova13 Department of Pathological Physiology and.
Vitezslav Kolek14 Department of Respiratory Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
Benjamin A Rybicki15 Department of Public Health Sciences, Henry Ford Health Systems, Detroit, Michigan; and.
Michael C Iannuzzi16 State University of New York Upstate Medical University Syracuse, Syracuse, New York.
Martin Petrek13 Department of Pathological Physiology and.
Jan C Grutters11 Center of Interstitial Lung Diseases, St. Antonius Hospital, Nieuwegein, the Netherlands.
Courtney Montgomery10 Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
Annegret Fischer4 Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Anders Eklund1 Respiratory Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Leonid Padyukov2 Center for Molecular Medicine, and.
Johan Grunewald2 Center for Molecular Medicine, and.
Christian-Albrechts-Universität zu Kiel · DEKarolinska Institutet · SEKarolinska University Hospital · SEOklahoma Medical Research Foundation · USUniversity Medical Center Utrecht · NLHenry Ford Health System · USPalacký University Olomouc · CZSt. Antonius Ziekenhuis · NLSUNY Upstate Medical University · USUniversity of Bonn · DEUniversity of Freiburg · DE

Funding

Comprehensive Genome Interrogation of African American Sarcoidosis FamiliesR01HL113326 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI MONTGOMERY, COURTNEY · 2012 to 2022
$8.7M
Quantitative Analysis Core P30GM110766 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GAFFNEY, PATRICK M · 2014 to 2018
$6.1M
NHLBI NIH HHS R01 HL113326NIGMS NIH HHS P30 GM110766
6 · The paper itself

Abstract

rationaleSarcoidosis is a multisystem disease of unknown cause. Löfgren's syndrome (LS) is a characteristic subgroup of sarcoidosis that is associated with a good prognosis in sarcoidosis. However, little is known about its genetic architecture or its broader phenotype, non-LS sarcoidosis.

objectivesTo address the genetic architecture of sarcoidosis phenotypes, LS and non-LS.

methodsAn association study in a white Swedish cohort of 384 LS, 664 non-LS, and 2,086 control subjects, totaling 3,134 subjects using a fine-mapping genotyping platform was conducted. Replication was performed in four independent cohorts, three of white European descent (Germany, n = 4,975; the Netherlands, n = 613; and Czech Republic, n = 521), and one of black African descent (United States, n = 1,657), totaling 7,766 subjects. MEASUREMENTS AND MAIN

resultsA total of 727 LS-associated variants expanding throughout the extended major histocompatibility complex (MHC) region and 68 non-LS-associated variants located in the MHC class II region were identified and confirmed. A shared overlap between LS and non-LS defined by 17 variants located in the MHC class II region was found. Outside the MHC region, two LS-associated loci, in ADCY3 and between CSMD1 and MCPH1, were observed and replicated.

conclusionsComprehensive and integrative analyses of genetics, transcription, and pathway modeling on LS and non-LS indicates that these sarcoidosis phenotypes have different genetic susceptibility, genomic distributions, and cellular activities, suggesting distinct molecular mechanisms in pathways related to immune response with a common region.

Indexed as

GenotypePhenotypeCzech RepublicFemaleGenetic Predisposition to DiseaseGenomicsGermanyHumansMaleMiddle AgedNetherlandsSarcoidosis, PulmonarySwedenUnited Statesgenetic epidemiology of sarcoidosisgenome-wide associationsImmunochipLöfgren’s syndromenon-Löfgren’s syndrome

Identifiers

PMID26651848
PMCPMC4872654
OpenAlexW2190867064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.